SCHEMBL4488292

SCHEMBL4488292

CC(C(=O)O)c1ccc(C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.61
PTGS1 P23219 7/20 0.57
CYP2C9 P11712 4/20 0.57
LMNA P02545 4/20 0.57
AKR1C3 P42330 4/20 0.57
CXCR1 P25024 4/20 0.57
CXCR2 P25025 4/20 0.57
AKR1C2 P52895 3/20 0.57
TSHR P16473 2/20 0.57
SLC22A6 Q4U2R8 2/20 0.57
CXCL8 P10145 2/20 0.57
PMP22 Q01453 2/20 0.57
ALB P02768 1/20 0.57
ESR1 P03372 1/20 0.57
ALOX5 P09917 1/20 0.57
RARB P10826 1/20 0.57
ADRB3 P13945 1/20 0.57
NFKB1 P19838 1/20 0.57
HTR2A P28223 1/20 0.57
NR1I3 Q14994 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6688306 1.00 PTGS2 (0.61) PTGS2PTGS1CYP2C9LMNAAKR1C3
SCHEMBL10936588 0.89 TSHR (0.52) PTGS2PTGS1CYP2C9LMNAAKR1C3
SCHEMBL59197 0.88 PTGS2 (0.74) PTGS2PTGS1CYP2C9LMNAAKR1C3
Benzoic Acid SCHEMBL8935150 0.87 PTGS2 (0.62) PTGS2PTGS1CYP2C9LMNAAKR1C3
Benzoic Acid SCHEMBL5786013 0.87 PTGS2 (0.62) PTGS2PTGS1CYP2C9LMNAAKR1C3
SCHEMBL8833485 0.86 TSHR (0.55) PTGS2TSHRTP53ALDH1A1HPGD
SCHEMBL5569785 0.84 TSHR (0.52) PTGS2TSHRTP53ALDH1A1HPGD
SCHEMBL10958350 0.84 PTGS2 (0.59) PTGS2PTGS1CYP2C9LMNAAKR1C3
SCHEMBL9577279 0.83 TSHR (0.50) PTGS2CYP2C9TSHRTP53ALDH1A1
SCHEMBL6070671 0.83 PTGS2 (0.57) PTGS2PTGS1CYP2C9LMNAAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119064487-A Method for detecting related substances of loxoprofen sodium gel plaster 江苏济茗医药有限公司 2024-12-03 CN claimed
CN-109180507-B Ketoprofen hapten, artificial antigen and antibody, and preparation method and application thereof 北京勤邦生物技术有限公司 2022-10-21 CN claimed
CN-109180507-A Ketoprofen haptens, artificial antigen and antibody and its preparation method and application 北京勤邦生物技术有限公司 2019-01-11 CN claimed
US-4031167-A COATINGS INTERNATIONAL TELEPHONE AND TELEGRAPH CORPORATION (US) 1977-06-21 US claimed
CN-109180507-B Ketoprofen hapten, artificial antigen and antibody, and preparation method and application thereof 北京勤邦生物技术有限公司 2022-10-21 CN disclosed
WO-2019233215-A1 HIGH WATER-REDUCING AND LOW SENSITIVITY POLYCARBOXYLATE SUPERPLASTICIZER AND PREPARATION METHOD THEREFOR 科之杰新材料集团有限公司 (CN) 2019-12-12 WO disclosed
CN-110294659-A A kind of preparation method of organic carboxyl acid 中国科学院兰州化学物理研究所苏州研究院 2019-10-01 CN disclosed
CN-109180507-A Ketoprofen haptens, artificial antigen and antibody and its preparation method and application 北京勤邦生物技术有限公司 2019-01-11 CN disclosed
EP-2427435-B1 SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS MEDIFRON DBT INC (KR) 2017-06-14 EP disclosed
US-9624209-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2017-04-18 US disclosed
US-9624209-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2017-04-18 US disclosed
CN-105085555-A Dimensional cadmium polymer containing mixed ligand as well as preparation method and application thereof UNIV QILU TECHNOLOGY 2015-11-25 CN disclosed
WO-2010127856-A1 SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2010-11-11 WO disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
WO-2004091522-A2 METHOD FOR TREATING NEURODEGENERATIVE DISORDERS MYRIAD GENETICS, INC. (US) 2004-10-28 WO disclosed
US-5454910-A Pulp-like short fibers from liquid crystal polyesters KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1995-10-03 US disclosed
EP-0330241-A2 Calcitonin derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-08-30 EP disclosed
EP-0013461-B1 PROCESS FOR THE PREPARATION OF A SEGMENTED THERMOPLASTIC ELASTOMER AKZO N.V. (NL) 1983-04-06 EP disclosed
EP-0013461-A1 Process for the preparation of a segmented thermoplastic elastomer AKZO N.V. (NL) 1980-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PTGS2 1937/4885PTGS1 1195/4885CYP2C9 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.